Bal Pharma Ltd

NSE
BALPHARMA •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Bal Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
84.21% Gain from 52W Low
10.5
TTM PE Ratio
High in industry
52.4
Price to Book Ratio
Below industry Median
2.9
Dividend yield 1yr %
Above industry Median
0.9
TTM PEG Ratio
PEG TTM is much higher than 1
4.8
RSI
RSI is mid-range
48.5
MFI
MFI is mid-range
52.4

Bal Pharma Ltd Key Financials

*All values are in ₹ Cr.

Bal Pharma Ltd shareholding Pattern

Promoter
51.2%
Foreign Institutions
0.1%
Public
48.6%

Bal Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
7
Bearish Moving Averages
9
5Day EMA
118.00
10Day EMA
118.60
12Day EMA
118.70
20Day EMA
118.50
26Day EMA
117.90
50Day EMA
114.50
100Day EMA
108.50
200Day EMA
101.80
Delivery & Volume
Resistance & Support
117.35
Pivot
Resistance
First Resistance
119.20
Second Resistance
121.70
Third Resistance
123.55
Support
First Support
114.85
Second support
113
Third Support
110.50
Relative Strength Index
48.47
Money Flow Index
52.37
MACD
0.77
MACD Signal
1.64
Average True Range
6.90
Average Directional Index
18.14
Rate of Change (21)
2.06
Rate of Change (125)
24.02

Bal Pharma Ltd Company background

Founded in: 1987
Managing director: Shailesh Siroya
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May 87. In Mar.90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations.BPL manufactures and markets pharmaceutical formulations paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.95 for manufacture of bulk drugs and expansion of pharmaceutical formulations.During 199798, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The companys product range has been expanded with the introduction of AZIWIN, CAFIMOL CORTIDERM.The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium M, Progit MPS in its ethical division during 19992000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named SERVETUS has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 201415 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 201617, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 201718, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drugsmanufacturing unit at Yadgir District , Karnataka in year 202223. It launched Sitagliptin (a DPP4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND SITABENDM, respectively in 2023.
Read More

Bal Pharma Ltd FAQs

Bal Pharma Ltd shares are currently priced at 116.7 on NSE and 116.65 on BSE as of 2/22/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Bal Pharma Ltd [BALPHARMA] share was 59.53. The Bal Pharma Ltd [BALPHARMA] share hit a 1-year low of Rs. 63.35 and a 1-year high of Rs. 132.45.

The market cap of Bal Pharma Ltd is Rs. 184.44 Cr. as of 2/22/2024 12:00:00 AM.

The PE ratios of Bal Pharma Ltd is 29.83 as of 2/22/2024 12:00:00 AM.

The PB ratios of Bal Pharma Ltd is 1.89 as of 2/22/2024 12:00:00 AM

You can easily buy Bal Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage